XM Therapeutics is a Brown University spinoff developing tissue repair and regeneration therapies for chronic disorders where an impaired healing response leads to progressive fibrosis (scarring), inflammation, and hypoxia. Applying cutting edge proteomic and 3D cell culture technologies, XM designs acellular human Extracellular Matrix particles that engraft and modify the affected tissue, thereby reducing fibrosis and improving blood flow and organ function. Our preclinical proof of concept includes ischemic heart failure and chronic wound healing. Other indications will be pursued and developed in partnerships.